Maxim analyst Jason McCarthy initiated coverage of Akari Therapeutics (AKTX) with a Buy rating and $5 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics Shareholders Approve Key AGM Resolutions
- Akari Therapeutics releases ‘What This Means’ segment for investors
- Akari Therapeutics announces granting of patent protection in India
- Akari Therapeutics price target raised to $7 from $4 at Alliance Global
- Akari Therapeutics releases ‘Meet the Team’ video